Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
2024 Australia-New Zealand Expert Consensus Statement on Cardiac Amyloidosis.
Bart NK, Fatkin D, Gunton J, Hare JL, Korczyk D, Kwok F, Lam K, Russell D, Sidiqi H, Sutton T, Gibbs SDJ, Mollee P, Thomas L. Bart NK, et al. Among authors: mollee p. Heart Lung Circ. 2024 Apr;33(4):420-442. doi: 10.1016/j.hlc.2023.11.027. Epub 2024 Apr 2. Heart Lung Circ. 2024. PMID: 38570258 Free article. Review.
Cardiac "hypertrophy" phenotyping: differentiating aetiologies with increased left ventricular wall thickness on echocardiography.
Ferkh A, Tjahjadi C, Stefani L, Geenty P, Byth K, De Silva K, Boyd AC, Richards D, Mollee P, Korczyk D, Taylor MS, Kwok F, Kizana E, Ng ACT, Thomas L. Ferkh A, et al. Among authors: mollee p. Front Cardiovasc Med. 2023 Jul 3;10:1183485. doi: 10.3389/fcvm.2023.1183485. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37465456 Free PMC article.
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
Adams D, Tournev IL, Taylor MS, Coelho T, Planté-Bordeneuve V, Berk JL, González-Duarte A, Gillmore JD, Low SC, Sekijima Y, Obici L, Chen C, Badri P, Arum SM, Vest J, Polydefkis M; HELIOS-A Collaborators. Adams D, et al. Amyloid. 2023 Mar;30(1):1-9. doi: 10.1080/13506129.2022.2091985. Epub 2022 Jul 23. Amyloid. 2023. PMID: 35875890 Clinical Trial.
Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma (AMaRC 03-16).
Mollee P, Reynolds J, Janowski W, Quach H, Campbell P, Gibbs S, Lee S, Lee E, Taylor K, Cochrane T, Wallington-Gates C, Kwok F, Weber N, Kerridge I, Weston H, Ho PJ, Leahy MF, Horvath N, Spencer A. Mollee P, et al. Blood Adv. 2024 May 13:bloodadvances.2023012539. doi: 10.1182/bloodadvances.2023012539. Online ahead of print. Blood Adv. 2024. PMID: 38739707
Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment-An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse.
Ho PJ, Spencer A, Mollee P, Bryant CE, Enjeti AK, Horvath N, Butcher BE, Trotman J, Gibbs S, Joshua DE. Ho PJ, et al. Among authors: mollee p. Clin Lymphoma Myeloma Leuk. 2024 Apr 7:S2152-2650(24)00149-6. doi: 10.1016/j.clml.2024.04.001. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38702217
Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study.
Ninkovic S, Harrison SJ, Lee JJ, Murphy N, Lee JH, Estell J, Chen VM, Horvath N, Kim K, Eek R, Augustson B, Bang SM, Huang SY, Rajagopal R, Szabo F, Engeler D, Butcher BE, Mollee P, Durie B, Chng WJ, Quach H. Ninkovic S, et al. Among authors: mollee p. Haematologica. 2024 Jan 18. doi: 10.3324/haematol.2023.284238. Online ahead of print. Haematologica. 2024. PMID: 38235519 Free article.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.
Screening for and diagnosis of monoclonal gammopathy.
Chong YP, Lim SM, Loh TP, Mollee P, Wijeratne N, Choy KW. Chong YP, et al. Among authors: mollee p. J Clin Pathol. 2023 Nov;76(11):727-733. doi: 10.1136/jcp-2023-208774. Epub 2023 Aug 21. J Clin Pathol. 2023. PMID: 37604683
Safety, Feasibility, and Acceptability of a Multisite Individualized Exercise Intervention for People with Multiple Myeloma.
Nicol JL, Cunningham BJ, Woodrow C, Adlard KN, Papinczak ZE, Spence RR, Boytar AN, Mollee P, Weber N, Nicol AJ, Hill MM, Skinner TL. Nicol JL, et al. Among authors: mollee p. Med Sci Sports Exerc. 2023 Dec 1;55(12):2214-2227. doi: 10.1249/MSS.0000000000003267. Epub 2023 Aug 2. Med Sci Sports Exerc. 2023. PMID: 37535331 Clinical Trial.
177 results